[1] STEPHAN SR, SHALLOP B, LACKMAN R, et al. Pigmented villonodular synovitis: a comprehensive review and proposed treatment algorithm. JBJS Rev. 2016;4(7):e3.
[2] SBARAGLIA M, BELLAN E, DEI TOS AP. The 2020 WHO Classification of soft tissue tumours: news and perspectives. Pathologica. 2021;113(2):70-84.
[3] CHIANG ER, MA HL, WANG JP, et al. Multi-lineage differentiation and angiogenesis potentials of pigmented villonodular synovitis derived mesenchymal stem cells--pathological implication. J Orthop Res. 2016;34(3):395-403.
[4] BERNTHAL NM, ISHMAEL CR, BURKE ZDC. Management of pigmented villonodular synovitis (PVNS): an orthopedic surgeon’s perspective. Curr Oncol Rep. 2020;22(6):63.
[5] QUARESMA MB, PORTELA J, SOARES DO BRITO J. Open versus arthroscopic surgery for diffuse tenosynovial giant-cell tumours of the knee: a systematic review. EFORT Open Rev. 2020;5(6):339-346.
[6] KAGER M, KAGER R, FAŁEK P, et al. Tenosynovial giant cell tumor. Folia Med Cracov. 2022;62(2):93-107.
[7] DEGIRMENCI E, SAHIN AA, BULUM YE, et al. Diffuse-type giant cell tumor: pigmented villonodular synovitis of patellar fat pad. J Cancer Res Ther. 2022;18(4):1189-1191.
[8] STAALS EL, FERRARI S, DONATI DM, et al. Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives. Eur J Cancer. 2016;63:34-40.
[9] PALMERINI E, STAALS EL. Treatment updates on tenosynovial giant cell tumor. Curr Opin Oncol. 2022;34(4):322-327.
[10] BRAHMI M, VINCENEUX A, CASSIER PA. Current systemic treatment options for tenosynovial giant cell tumor/pigmented villonodular synovitis: targeting the CSF1/CSF1R axis. Curr Treat Options Oncol. 2016;17(2):10.
[11] VERSPOOR FGM, MASTBOOM MJL, HANNINK G, et al. The effect of surgery in tenosynovial giant cell tumours as measured by patient-reported outcomes on quality of life and joint function. Bone Joint J. 2019;101-B(3):272-280.
[12] CHEN C, DUBIN R, KIM MC. Emerging trends and new developments in regenerative medicine: a scientometric update (2000 -2014). Expert Opin Biol Ther. 2014;14(9):1295-1317.
[13] 陈悦,陈超美,刘则渊,等.CiteSpace知识图谱的方法论功能[J].科学学研究, 2015,33(2):242-253.
[14] HIRSCH JE. An index to quantify an individual’s scientific research output. Proc Natl Acad Sci U S A. 2005;102(46): 16569-16572.
[15] OTTAVIANI S, AYRAL X, DOUGADOS M, et al. Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature. Semin Arthritis Rheum. 2011;40(6):539-546.
[16] MURPHEY MD, RHEE JH, LEWIS RB, et al. Pigmented villonodular synovitis: radiologic-pathologic correlation. Radiographics. 2008;28(5):1493-1518.
[17] CASSIER PA, GELDERBLOM H, STACCHIOTTI S, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer. 2012;118(6):1649-1655.
[18] WEST RB, RUBIN BP, MILLER MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A. 2006;103(3): 690-695.
[19] RAVI V, WANG WL, LEWIS VO. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Curr Opin Oncol. 2011;23(4):361-366.
[20] SHARMA V, CHENG EY. Outcomes after excision of pigmented villonodular synovitis of the knee. Clin Orthop Relat Res. 2009; 467(11):2852-2858.
[21] SHABAT S, KOLLENDER Y, MERIMSKY O, et al. The use of surgery and yttrium 90 in the management of extensive and diffuse pigmented villonodular synovitis of large joints. Rheumatology (Oxford). 2002; 41(10):1113-1118.
[22] BLAY JY, EL SAYADI H, THIESSE P, et al. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol. 2008;19(4):821-822.
[23] CUPP JS, MILLER MA, MONTGOMERY KD, et al. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides. Am J Surg Pathol. 2007;31(6):970-976.
[24] CASSIER PA, ITALIANO A, GOMEZ-ROCA CA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015;16(8): 949-956.
[25] MASTBOOM MJL, HOEK DM, BOVÉE JVMG, et al. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee? Histopathology. 2019;74(2): 332-340.
[26] DALE K, SMITH HJ, PAUS AC, et al. Dynamic MR-imaging in the diagnosis of pigmented villonodular synovitis of the knee. Scand J Rheumatol. 2000;29(5):336-339.
[27] MYERS BW, MASI AT. Pigmented villonodular synovitis and tenosynovitis: a clinical epidemiologic study of 166 cases and literature review. Medicine (Baltimore). 1980;59(3):223-238.
[28] GOUIN F, NOAILLES T. Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis). Orthop Traumatol Surg Res. 2017; 103(1S):S91-S97.
[29] XIE GP, JIANG N, LIANG CX, et al. Pigmented villonodular synovitis: a retrospective multicenter study of 237 cases. PLoS One. 2015;10(3):e0121451.
[30] FOTIADIS E, PAPADOPOULOS A, SVARNAS T, et al. Giant cell tumour of tendon sheath of the digits. A systematic review. Hand (N Y). 2011;6(3):244-249.
[31] DAOUD J, AOUAD D, HASSAN Y, et al. Localized pigmented villonodular synovitis of the posterior knee compartment with popliteal vessel compression: a case report of arthroscopic resection using only anterior knee portals. Case Rep Orthop. 2018; 2018:7532358.
[32] DINES JS, DEBERARDINO TM, WELLS JL, et al. Long-term follow-up of surgically treated localized pigmented villonodular synovitis of the knee. Arthroscopy. 2007;23(9):930-937.
[33] GU HF, ZHANG SJ, ZHAO C, et al. A comparison of open and arthroscopic surgery for treatment of diffuse pigmented villonodular synovitis of the knee. Knee Surg Sports Traumatol Arthrosc. 2014;22(11): 2830-2836.
[34] MOLLON B, LEE A, BUSSE JW, et al, Theodoropoulos J. The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee: an individual patient meta-analysis. Bone Joint J. 2015;97-B(4): 550-557.
[35] GELDERBLOM H, DE SANDE MV. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor. Future Oncol. 2020;16(29): 2345-2356.
|